Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedJul 17, 2019Hydroxocobalamin 10 mg/mL InjectionLack of Assurance of Sterility.First Pharma Associates LLC dba Riverpoint Pharmacy · D-1476-2019Class IITerminatedJul 17, 2019Prostaglandin 20 mcg/mL/Procaine 0.1% InjectionLack of Assurance of Sterility.First Pharma Associates LLC dba Riverpoint Pharmacy · D-1475-2019Class IITerminatedJul 17, 2019Hydroxyprogesterone Caproate 250 mg/mL Sesame Oil InjectionLack of Assurance of Sterility.First Pharma Associates LLC dba Riverpoint Pharmacy · D-1474-2019Class IITerminatedJul 17, 2019Testosterone Cyp/Estradiol Cyp 50 mg/2.5 mg/mL InjectionLack of Assurance of Sterility.First Pharma Associates LLC dba Riverpoint Pharmacy · D-1473-2019Class IITerminatedJul 17, 2019Testosterone Cypionate 100 mg/mLOil Injection InjectionLack of Assurance of Sterility.First Pharma Associates LLC dba Riverpoint Pharmacy · D-1472-2019Class IITerminatedJul 17, 2019Testosterone Cypionate 200 mg/mL Ethyl Oleate InjectionLack of Assurance of Sterility.First Pharma Associates LLC dba Riverpoint Pharmacy · D-1471-2019Class IITerminatedJul 17, 2019Testosterone Cypionate 200 mg/mL Sesame Oil InjectionLack of Assurance of Sterility.First Pharma Associates LLC dba Riverpoint Pharmacy · D-1470-2019Class IITerminatedJul 17, 2019Testosterone Cypionate 150 mg/mL Sesame Oil InjectionLack of Assurance of Sterility.First Pharma Associates LLC dba Riverpoint Pharmacy · D-1469-2019Class IITerminatedJul 17, 2019Testosterone Cypionate 100 mg/mL Sesame Oil InjectionLack of Assurance of Sterility.First Pharma Associates LLC dba Riverpoint Pharmacy · D-1468-2019Class IITerminatedJul 17, 2019Anastrozole TabletsGMP Deviations: Potential cross contamination due to cleaning procedure failure.American Health Packaging · D-1467-2019Class IITerminatedJul 17, 2019Losartan Potassium TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at...Major Pharmaceuticals · D-1466-2019Class IITerminatedJul 17, 2019Losartan PotassiumCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Golden State Medical Supply Inc. · D-1465-2019Class IITerminatedJul 17, 2019Losartan PotassiumCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Golden State Medical Supply Inc. · D-1464-2019Class IITerminatedJul 17, 2019Losartan PotassiumCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Golden State Medical Supply Inc. · D-1463-2019Class IITerminatedJul 17, 2019Losartan PotassiumCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Golden State Medical Supply Inc. · D-1462-2019Class IITerminatedJul 17, 2019Losartan Potassium andHydrochlorothiazide Tablets 100 mg/25 mg 90 tabletsCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Macleods Pharma Usa Inc · D-1461-2019Class IITerminatedJul 17, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Macleods Pharma Usa Inc · D-1460-2019Class IITerminatedJul 17, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Macleods Pharma Usa Inc · D-1459-2019Class IITerminatedJul 17, 2019Losartan Potassium Tablets 50 mg 1000 TabletsCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Macleods Pharma Usa Inc · D-1458-2019Class IITerminatedJul 17, 2019Losartan Potassium TabletsCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Macleods Pharma Usa Inc · D-1457-2019Class IIOngoingJul 17, 2019LOSARTAN POTASSIUM 100 mg TABLET BULKCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Teva Pharmaceuticals USA · D-1456-2019Class IIOngoingJul 17, 2019LOSARTAN POTASSIUM 50 mg TABLET BULKCGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.Teva Pharmaceuticals USA · D-1455-2019Class ITerminatedJul 10, 2019Hydromorphone HCl in 0.9% sodium chlorideIncorrect Product Formulation; Firm's customer resource center (CRC) statement indicates that the product is sulfite free, however the product is produced with a raw...PharMEDium Services, LLC · D-1488-2019Class IIITerminatedJul 10, 2019Testosterone Topical Solution 30mg of testosterone per pump actuation * each actuation delivers 1.5 mL of...Defective Container; actuator may improperly function and affect dose delivery.InvaGen Pharmaceuticals, Inc. · D-1454-2019Class IIITerminatedJul 10, 2019Esterified Estrogens & Methyltestosterone TabletsSubpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone tablets.Amneal Pharmaceuticals, Inc. · D-1439-2019Class IIITerminatedJul 10, 2019Esterified Estrogens & Methyltestosterone TabletsSubpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone tablets.Amneal Pharmaceuticals, Inc. · D-1438-2019Class IITerminatedJul 3, 2019Pramipexole Dihydrochloride TabletsGMP Deviations; possible cross contamination of product due to cleaning procedure failure.American Health Packaging · D-1434-2019Class IITerminatedJul 3, 2019Pramipexole Dihydrochloride TabletsGMP Deviations; possible cross contamination of product due to cleaning procedure failure.American Health Packaging · D-1433-2019Class IITerminatedJul 3, 2019Pramipexole Dihydrochloride TabletsGMP Deviations; possible cross contamination of product due to cleaning procedure failure.American Health Packaging · D-1432-2019Class IITerminatedJul 3, 2019Pramipexole Dihydrochloride TabletsGMP Deviations; possible cross contamination of product due to cleaning procedure failure.American Health Packaging · D-1431-2019Class IITerminatedJul 3, 2019Diphenhydramine HCL LiquidMicrobial Contamination of Non-sterile Products: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).H J Harkins Company Inc dba Pharma Pac · D-1430-2019Class IITerminatedJul 3, 2019Acetaminophen Children's LiquidMicrobial Contamination of Non-sterile Products: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).H J Harkins Company Inc dba Pharma Pac · D-1429-2019Class IITerminatedJul 3, 2019SUCCINYLcholine ChlorideLack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations...Premier Pharmacy Labs Inc · D-1428-2019Class IITerminatedJul 3, 2019SUCCINYLcholine ChlorideLack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations...Premier Pharmacy Labs Inc · D-1427-2019Class IITerminatedJul 3, 2019Sodium Bicarbonate INJ 8.4%Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations...Premier Pharmacy Labs Inc · D-1426-2019Class IITerminatedJul 3, 2019Riboflavin 5-Phosphate Sodium Ophthalmic SolutionLack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations...Premier Pharmacy Labs Inc · D-1425-2019Class IITerminatedJul 3, 2019Phenylephrine HCL PF INJ in 0.9% Sodium ChlorideLack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations...Premier Pharmacy Labs Inc · D-1424-2019Class IITerminatedJul 3, 2019Orphenadrine Citrate Sterile Injectable Solution *Contains Sulfites*Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations...Premier Pharmacy Labs Inc · D-1423-2019Class IITerminatedJul 3, 2019Neostigmine MethylsulfateLack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations...Premier Pharmacy Labs Inc · D-1422-2019Class IITerminatedJul 3, 2019Naloxone HCL Preserved INJLack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations...Premier Pharmacy Labs Inc · D-1421-2019